Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/IIa study of SSS40 for moderate to severe bone metastasis cancer pain
CTR20240053Phase 2Active
- Sponsor
- 3SBio
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of sss40 in bone metastases, sponsored by 3SBio. Started Apr 2024; status: active.
02
Drugs
sss40
03
Conditions
bone metastases
Beyond the preview
Go deeper on CTR20240053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240053.